Biocon shares rise 2% after USFDA approval for osteoporosis and bone loss drugs
Shares of Biocon Ltd rose 2% to Rs 361.25 on the BSE after its subsidiary, Biocon Biologics, received U.S. FDA approval for two denosumab biosimilars, Bosaya and Aukelso. The regulator also granted provisional interchangeability for both drugs, allowing pharmacy-level substitution, which could (...)
Site référencé: The Economic Times
The Economic Times
Flat markets, GST cuts, and the next big bets : Aparna Shanker on where to invest now
19/09/2025
Trump asks US Supreme Court to allow firing of Fed Governor Lisa Cook
19/09/2025
Asian stocks rise as global gauge hits new peak
19/09/2025
Sebi gives clean chit to Adani on Hindenburg allegations
19/09/2025
US vetoes UN resolution on Gaza ceasefire for an immediate and permanent ceasefire
19/09/2025
Will Saatvik Green Energy IPO spark long-term value for investors ?
19/09/2025
